亚太地区系统性曲霉病和系统性念珠菌病市场预测至 2027 年 - COVID-19 影响和按类型划分的区域分析(伏立康唑、脂质体、两性霉素 B、系统性口服唑类药物、外用药物、抗真菌药物等);应用(慢性肺曲霉病(CPA)、过敏性支气管肺曲霉病(ABPA)、胃肠道念珠菌病、泌尿生殖道念珠菌病等);和国家

Historic Data: 2017-2018   |   Base Year: 2019   |   Forecast Period: 2020-2027


No. of Pages: 96    |    Report Code: TIPRE00020063    |    Category: Life Sciences

Asia Pacific Systemic Aspergillosis and Systemic Candidasis Market

市场介绍

真菌全身感染常见于免疫系统较弱的患者,包括免疫抑制和获得性免疫缺陷综合症(艾滋病)患者。全身症状包括呼吸暂停、愈创木脂阳性大便、腹胀、高血糖、类白血病反应、低血压等。系统性念珠菌病和曲霉菌病的治疗需要肠外抗真菌治疗,这种情况的死亡率很高。此外,这种感染可能会导致长期幸存者出现永久性神经发育缺陷。

市场概况和动态

亚洲太平洋系统性曲霉病和系统性念珠菌病市场预计将从 2019 年的 14.3777 亿美元增至 2027 年的 20.3054 亿美元;预计 2020 年至 2027 年复合年增长率为 4.5%。亚太地区系统性曲霉病和系统性念珠菌病市场的增长归因于真菌疾病患病率的上升以及医院获得性真菌感染的增加。然而,抗真菌药物的耐药性不断增加,抗真菌药物的副作用限制了该地区市场的增长。由于 COVID-19 的不断增长,亚太地区国家预计将面临巨大的挑战。受疫情影响,医疗保健行业受到严重影响,产品发布会、产品推介会等众多业务相关活动被推迟,从而制约了市场的增长。

主要细分市场

根据类型,亚太地区系统性曲霉病和系统性念珠菌病市场分为伏立康唑、脂质体、两性霉素 B、系统性口服唑类药物、外用药物、抗真菌药物, 和别的。 2019年,系统性口服唑类药物领域占据了更大的市场份额。预计在预测期内将以更快的速度增长。

主要来源和上市公司

在准备亚太地区系统性曲霉病和系统性念珠菌病市场报告时提到的一些主要一手和二手来源是世界卫生组织、卫生和预防部以及卫生和家庭福利部。

诺华公司、赛诺菲公司、辉瑞公司、默克公司Co., Inc.、拜耳 AG、安斯泰来制药公司、葛兰素史克公司、雅培、Cipla Inc.、Enzon Pharmaceuticals, Inc.。

 

购买报告的理由

  • 收件人了解亚太地区系统性曲霉病和系统性念珠菌病市场格局,并确定最有可能保证丰厚回报的细分市场
  • 在了解亚太地区不断变化的竞争格局方面保持领先地位亚太系统性曲霉病和系统性念珠菌病市场
  • 通过识别最有前途的细分市场,有效规划亚太系统性曲霉病和系统性念珠菌病市场的并购和合作交易可能的销售额
  • 通过对亚太地区系统性曲霉病和系统性念珠菌病市场各个细分市场的市场表现进行敏锐和全面的分析,帮助做出明智的业务决策
  • 获得亚太系统性曲霉病和系统性念珠菌病市场各个细分市场2019年至2027年的市场收入预测

亚太系统性曲霉菌病和全身性念珠菌病市场细分

按类型

  • 全身口服唑类药物
  • 伏立康唑
  • 脂质体两性霉素 B
  • 外用抗真菌药物
  • 其他

按应用

  • 过敏性支气管肺曲霉病(ABPA)
  • 慢性肺曲霉病(CPA)
  • 胃肠道念珠菌病
  • 泌尿生殖道念珠菌病
  • 其他

按国家/地区

  • 中国
  • 日本
  • 印度
  • 韩国
  • 澳大利亚
  • 亚太地区其他地区

公司简介

  • Novartis AG
  • 赛诺菲
  • 辉瑞公司
  • 默克公司Co., Inc.
  • 拜耳股份公司
  • 安斯泰来制药公司
  • 葛兰素史克公司
  • 雅培
  • Cipla Inc.
  • Enzon Pharmaceuticals, Inc.
 

Asia Pacific Systemic Aspergillosis and Systemic Candidasis Strategic Insights

Strategic insights for Asia Pacific Systemic Aspergillosis and Systemic Candidasis involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/asia-pacific-systemic-aspergillosis-and-systemic-candidasis-market-strategic-framework.webp
Get more information on this report

Asia Pacific Systemic Aspergillosis and Systemic Candidasis Report Scope

Report Attribute Details
Market size in 2019 US$ 1,437.77 Million
Market Size by 2027 US$ 2,030.54 Million
Global CAGR (2020 - 2027) 4.5%
Historical Data 2017-2018
Forecast period 2020-2027
Segments Covered By 类型
  • 伏立康唑
  • 脂质体
  • 两性霉素 B
  • 全身口服唑类
  • 外用
  • 抗真菌剂
By 应用
  • 慢性肺曲霉病
  • 过敏性
  • 支气管肺曲霉病
  • 胃肠道念珠菌病
  • 泌尿生殖道念珠菌病
Regions and Countries Covered 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
Market leaders and key company profiles
  • Novartis AG
  • Sanofi
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Bayer AG
  • Astellas Pharma Inc.
  • GlaxoSmithKline plc.
  • Abbott
  • Cipla Inc.
  • Enzon Pharmaceuticals, Inc.
  • Get more information on this report

    Asia Pacific Systemic Aspergillosis and Systemic Candidasis Regional Insights

    The regional scope of Asia Pacific Systemic Aspergillosis and Systemic Candidasis refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/asia-pacific-systemic-aspergillosis-and-systemic-candidasis-market-geography.webp
    Get more information on this report

    The List of Companies - Asia Pacific Systemic Aspergillosis and Systemic Candidasis Market

    1. Novartis AG
    2. Sanofi
    3. Pfizer Inc.
    4. Merck & Co., Inc.
    5. Bayer AG
    6. Astellas Pharma Inc.
    7. GlaxoSmithKline plc.
    8. Abbott
    9. Cipla Inc.
    10. Enzon Pharmaceuticals, Inc.
    Frequently Asked Questions
    How big is the Asia Pacific Systemic Aspergillosis and Systemic Candidasis Market?

    The Asia Pacific Systemic Aspergillosis and Systemic Candidasis Market is valued at US$ 1,437.77 Million in 2019, it is projected to reach US$ 2,030.54 Million by 2027.

    What is the CAGR for Asia Pacific Systemic Aspergillosis and Systemic Candidasis Market by (2020 - 2027)?

    As per our report Asia Pacific Systemic Aspergillosis and Systemic Candidasis Market, the market size is valued at US$ 1,437.77 Million in 2019, projecting it to reach US$ 2,030.54 Million by 2027. This translates to a CAGR of approximately 4.5% during the forecast period.

    What segments are covered in this report?

    The Asia Pacific Systemic Aspergillosis and Systemic Candidasis Market report typically cover these key segments-

  • 类型 (伏立康唑, 脂质体, 两性霉素 B, 全身口服唑类, 外用, 抗真菌剂)
  • 应用 (慢性肺曲霉病, 过敏性, 支气管肺曲霉病, 胃肠道念珠菌病, 泌尿生殖道念珠菌病)
  • What is the historic period, base year, and forecast period taken for Asia Pacific Systemic Aspergillosis and Systemic Candidasis Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Systemic Aspergillosis and Systemic Candidasis Market report:

  • Historic Period : 2017-2018
  • Base Year : 2019
  • Forecast Period : 2020-2027
  • Who are the major players in Asia Pacific Systemic Aspergillosis and Systemic Candidasis Market?

    The Asia Pacific Systemic Aspergillosis and Systemic Candidasis Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Novartis AG
  • Sanofi
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Bayer AG
  • Astellas Pharma Inc.
  • GlaxoSmithKline plc.
  • Abbott
  • Cipla Inc.
  • Enzon Pharmaceuticals, Inc.
  • Who should buy this report?

    The Asia Pacific Systemic Aspergillosis and Systemic Candidasis Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Asia Pacific Systemic Aspergillosis and Systemic Candidasis Market value chain can benefit from the information contained in a comprehensive market report.